Abbott announced a definitive agreement to acquire Exact Sciences for approximately $21 billion in cash, expanding Abbott’s diagnostics footprint into cancer screening and precision oncology. Exact Sciences brings Cologuard, Oncotype DX, Oncodetect and emerging multi-cancer early detection and MRD tests. Abbott said the deal will be immediately accretive to revenue growth and gross margin and aims to close in Q2 2026. The acquisition combines Abbott’s global commercial reach and manufacturing scale with Exact’s test portfolio and R&D, positioning Abbott to expand access to cancer screening and longitudinal oncology monitoring.